StockData
Pfizer Inc logo

Pfizer Inc

PFENYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 28, 2026Last filing: 10-Q on Aug 4, 2026Score 11/3053% above fair value
$30.52+0.57 (+1.90%)

Close on Oct 30, 2026Market cap $173.95BP/E 40.2Yield 5.64%

Pfizer Padcev (enfortumab vedotin ADC by Year

Padcev (enfortumab vedotin ADC — urothelial cancer, via Seagen) — Worldwide revenues ($M) ($M)

QuarterlyAnnual

Pfizer Padcev (enfortumab vedotin ADC: $1,940M in FY2025, up 22.2% from a year earlier.

Latest, FY2025
1,940
Period ended Dec 31, 2025
Change on a year earlier
+22.2%
1,588 in FY2024
History
5 years
Since FY2021
Sources
4
Documents cited below

Where the FY2025 figure comes from

“|| Padcev | 1,940 | 1,588 | 22% | 22% | 1,902 | 1,561 | 22% | 38 | 27 | 42% | 43%”

Source: Form 8-K (Earnings / Guidance Release) (pfe-12312025xex99.htm, filed 2026-02-03) ↗

Reported in Form 8-K Revenue Tables & Form 10-Q / 10-K Segment Footnotes.

Annual history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedPadcev (enfortumab vedotin ADC — urothelial cancer, via Seagen) — Worldwide revenues ($M) ($M)Year on yearSource
FY2025Dec 31, 20251,940+22.2%Form 8-K (Earnings / Guidance Release) (pfe-12312025xex99.htm, filed 2026-02-03) ↗
FY2024Dec 31, 20241,588+2,896.2%Form 8-K (Earnings / Guidance Release) (pfe-12312025xex99.htm, filed 2026-02-03) ↗
FY2023Dec 31, 202353–Form 8-K (Earnings / Guidance Release) (pfe-12312024xex99.htm, filed 2025-02-04) ↗
FY2022Dec 31, 20220–Form 10-K (filed 2025-02-27) ↗
FY2021Dec 31, 20210–Form 10-K (filed 2024-02-22) ↗

Breakdown

What makes up padcev (enfortumab vedotin ADC

Cite this data

StockData. (2026). Pfizer Padcev (enfortumab vedotin ADC ($M), annual FY2021–FY2025 [Data set]. Compiled from Pfizer SEC filings and investor materials. https://stockdatahq.com/stocks/pfe/kpis/padcev-ww

See every metric in the Pfizer KPI table. Data updated Nov 2, 2026.